Edition:
India

Pluristem Therapeutics Inc (PSTI.OQ)

PSTI.OQ on NASDAQ Stock Exchange Capital Market

1.47USD
8 Dec 2017
Change (% chg)

$-0.02 (-1.34%)
Prev Close
$1.49
Open
$1.50
Day's High
$1.50
Day's Low
$1.47
Volume
23,224
Avg. Vol
106,655
52-wk High
$2.12
52-wk Low
$1.04

Select another date:

Mon, Nov 6 2017

BRIEF-Pluristem enters agreement with Tel Aviv Sourasky Medical Center to conduct phase i/ii trial in steroid-refractory chronic GvHD

* Pluristem enters into agreement with Tel Aviv Sourasky Medical Center to conduct phase i/ii trial in steroid-refractory chronic GvHD Source text for Eikon: Further company coverage:

BRIEF-PLURISTEM PRICES PUBLIC OFFERING OF COMMON STOCK ON THE TEL AVIV STOCK EXCHANGE

* PLURISTEM ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK ON THE TEL AVIV STOCK EXCHANGE

BRIEF-Pluristem extends trial for treatment of insufficient hematopoietic recovery

* Following approval of israel’s ministry of health, Pluristem extends its trial of plx-r18 to treat insufficient Hematopoietic recovery after bone marrow transplant and opens clinical centers in Israel

BRIEF-Pluristem expands its reach in the treatment of impaired hematopoietic systems

* Pluristem expands its reach in the treatment of impaired hematopoietic systems with a European patent covering PLX-R18 in chemotherapy, ARS, genetic disorders and autoimmune diseases Source text for Eikon: Further company coverage:

BRIEF-FDA grants Pluristem Orphan Drug Designation for its PLX-R18 cell therapy

* FDA grants Pluristem Orphan Drug Designation for its PLX-R18 cell therapy as treatment for acute radiation syndrome Source text for Eikon: Further company coverage:

BRIEF-Pluristem receives positive feedback from FDA and EMA as co prepares for Phase III trial of PLX-PAD

* Pluristem receives positive feedback from FDA and EMA as company prepares for Phase III trial of PLX-PAD to support recovery from hip fracture

BRIEF-U.S. FDA grants fast track designation to Pluristem's PLX-PAD for treating Critical Limb Ischemia

* U.S. FDA grants fast track designation to Pluristem's PLX-PAD for the treatment of Critical Limb Ischemia (cli)

BRIEF-Pluristem Therapeutics awarded two new patents in Hong Kong

* Awarded two new patents in Hong Kong for critical limb ischemia and muscle regeneration

BRIEF-U.S. DOD to conduct studies of Pluristem’s PLX-R18 in a new ARS project

* U.S. Department of Defense to conduct studies of Pluristem’s PLX-R18 in a new ars project for use before radiation exposure

BRIEF-Pluristem's ‍ARS study's new data shows hematological deficiencies even at low radiation levels​

* New data from ARS study shows significant hematological deficiencies even at low radiation levels; PLX-R18 supports hematological recovery​ Source text for Eikon: Further company coverage:

Select another date: